similar substances. The later phase (270–360 min) of edemainduced
by carrageenan is characterized by the highest
volume of hind limb, during which the edema reaches its
highest volume and by the presence of prostaglandins and
other slowly acting inflammatory mediators which include
kinin-like substances, i.e. prostaglandins, proteases and
lysosome [11,12]. These inflammation mediators are the
main components responsible for swelling and edematous
condition. Moreover, all the compounds were found safe after
48 h of test compound administration. Statistically, no
considerable difference was observed between the negative
control and other treatment groups both in terms of mortality
and morbidity.
This significant data of Taxusabietane A might share the
same anti-inflammatory mechanism as in the case of
indomethacin, which involves the inhibition of inflammation
process initiated through carrageenan [13]. Current investigations
regarding anti-inflammatory activities reveal the fact
that Taxusabietane A should be extensively studied further in
order to developed as a new lead compound for treatment of
inflammation.